These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 15844767

  • 21. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma.
    Strasser-Weippl K, Ludwig H.
    Eur J Haematol; 2008 Nov; 81(5):374-9. PubMed ID: 18637124
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV, Andreeva NE, Izgorodin AS.
    Ter Arkh; 1995 Nov; 67(7):35-9. PubMed ID: 7482303
    [Abstract] [Full Text] [Related]

  • 25. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma.
    Rossi D, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G, Gaidano G.
    Cancer; 2010 May 01; 116(9):2188-200. PubMed ID: 20198709
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P, Collacciani A, Maccarone C, Casale R.
    Biomed Pharmacother; 1996 May 01; 50(1):29-35. PubMed ID: 8672729
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.
    Bataille R, Grenier J, Sany J.
    Anticancer Res; 1987 May 01; 7(3 Pt B):513-5. PubMed ID: 3307602
    [Abstract] [Full Text] [Related]

  • 30. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D, Katodritou E, Zervas K.
    Hematology; 2007 Dec 01; 12(6):527-31. PubMed ID: 17852450
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of PINI index in patients with multiple myeloma.
    Dupire S, Wemeau M, Debarri H, Pascal L, Hivert B, Willekens C, Boyle E, Manier S, Béatrice T, Onraed B, Faucompré JL, Hennache B, Dumontet C, Facon T, Leleu X.
    Eur J Haematol; 2012 Apr 01; 88(4):306-13. PubMed ID: 22126676
    [Abstract] [Full Text] [Related]

  • 32. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
    Umeda M, Okuda S, Izumi H, Nagase D, Fujimoto Y, Sugasawa Y, Arai C, Natori K, Katoh M, Kuraishi Y.
    Ann Hematol; 2006 Jul 01; 85(7):469-73. PubMed ID: 16528526
    [Abstract] [Full Text] [Related]

  • 33. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
    Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, Kauczor HU, Ho AD, Goldschmidt H, Moehler TM.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):475-81. PubMed ID: 17255268
    [Abstract] [Full Text] [Related]

  • 34. Prognostic values of serum cystatin C and beta2 microglobulin, urinary beta2 microglobulin and N-acetyl-beta-D-glucosaminidase in early acute renal failure after liver transplantation.
    Hei ZQ, Li XY, Shen N, Pang HY, Zhou SL, Guan JQ.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1251-6. PubMed ID: 18713542
    [Abstract] [Full Text] [Related]

  • 35. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR.
    Semin Hematol; 2009 Apr 20; 46(2):110-7. PubMed ID: 19389494
    [Abstract] [Full Text] [Related]

  • 36. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
    Franco M, Fuzibet JG, Cassuto JP, Pesce A, Ziegler G, Dujardin P.
    Rev Rhum Mal Osteoartic; 1985 Nov 20; 52(11):619-23. PubMed ID: 3909365
    [Abstract] [Full Text] [Related]

  • 37. Serum beta-2-microglobulin in patients with multiple myeloma treated with alpha interferon.
    Murakami H, Ogawara H, Morita K, Saitoh T, Matsushima T, Tamura J, Sawamura M, Karasawa M, Miyawaki S, Schimano S, Satoh S, Tsuchiya J.
    J Med; 1997 Nov 20; 28(5-6):311-8. PubMed ID: 9604789
    [Abstract] [Full Text] [Related]

  • 38. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma.
    Takada S, Morita K, Hayashi K, Matsushima T, Sawamura M, Murakami H, Nojima Y.
    Eur J Haematol; 2005 Dec 20; 75(6):505-10. PubMed ID: 16313263
    [Abstract] [Full Text] [Related]

  • 39. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.
    Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gianelli U, Maiorana A, Merli F, Bellei M, Pozzi S, Stelitano C, Lazzaro A, Gobbi PG, Baldini L, Bergantini S, Fregoni V, Brugiatelli M.
    Haematologica; 2007 Nov 20; 92(11):1482-8. PubMed ID: 18024396
    [Abstract] [Full Text] [Related]

  • 40. [Clinical features and status in multiple myeloma].
    Sawamura M, Murakami H, Ogawara H, Tsuchiya J.
    Rinsho Ketsueki; 1993 Apr 20; 34(4):444-9. PubMed ID: 8510331
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.